The company has not filed an annual or quarterly report since its FY2020 10-K, filed Mar 1, 2021. Its latest SEC filing is a 15-12B from Mar 25, 2021.
10-K for FY2020, filed Mar 1, 2021
The sections below describe the company as of the FY2020 annual report.
Develops and sells medicines for autoimmune diseases, including Uplizna for neuromyelitis optica spectrum disorder, and advances other drug candidates for autoimmune conditions.
10-K for FY2020, filed Mar 1, 2021We are a biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, which we collectively refer to as…View ↗
Furthermore, we recently initiated a Phase 3 trial of inebilizumab for myasthenia gravis, a neuromuscular disorder caused by autoantibodies…View ↗
In addition, we have a broad pipeline of two additional clinical-stage and two pre-clinical product candidates focused on a number of other…View ↗
Specialty distributors and pharmacies pay for Uplizna when they receive and accept the product. For partner territories, the company may receive milestone payments and royalties on sales; payments for supplied product are invoiced at shipment, with amounts above cost tied to partner sales.
10-K for FY2020, filed Mar 1, 2021The Company’s contracts with its specialty distributor (the “SD”) and specialty pharmacy (the “SP”), referred to as its customers, are…View ↗
Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the…View ↗
Regulatory applications have also been filed in several other countries for inebilizumab in patients with NMOSD, based on results from the…View ↗
$11.7M
10-K for FY2020, filed Mar 1, 2021
$11.7M ↗
Specialty distributors and specialty pharmacies buy Uplizna directly. In Asia, Mitsubishi Tanabe Pharma and Hansoh Pharma are partners responsible for commercializing inebilizumab in their territories if approved.
10-K for FY2020, filed Mar 1, 2021
No. It lost $150.7M in FY2020.
10-K for FY2020, filed Mar 1, 2021
10-K for FY2020, filed Mar 1, 2021
−$153.9MView ↗
10-K for FY2020, filed Mar 1, 2021
−$150.7MView ↗
10-K for FY2020, filed Mar 1, 2021
−$107MView ↗
8-K, filed Mar 15, 2021
As described in the Introductory Note, on March 13, 2021, Purchaser irrevocably accepted for payment all Company Shares validly tendered…View ↗
Shrank.
Revenue fell 77% in 1 year, from $50M in FY2019 to $11.7M in FY2020, about 77% a year.
10-K for FY2020, filed Mar 1, 2021
Competes with Alexion Pharmaceuticals, Genentech, Chugai Pharmaceutical, Genentech USA, Bristol-Myers Squib, UCB, Biogen, Boehringer Ingelheim, AbbVie, and Novartis
10-K for FY2020, filed Mar 1, 2021Uplizna® competes with eculizumab from Alexion Pharmaceuticals, Inc., or Alexion, marketed as Soliris®, and satralizumab from Genentech…View ↗
Loading...
